Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 150-157

  Passiglia, Francesco ^a   Bronte, Giuseppe ^a   Bazan, Viviana ^a   Galvano, Antonio ^a   Vincenzi, Bruno ^b   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker

Indexed keywords

TUMOR MARKER;

BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; GENE MUTATION; GENETIC MARKER; HUMAN; LIVER METASTASIS; LIVER RESECTION; META ANALYSIS; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW;

EID: 84959561948     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.12.015     Document Type: Review

References (57)

1. Adam R., Hoti E., Folprecht G., Benson A.B. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest. Cancer Res. 2009, 3:S15-S22.
2. Ahn T.S., et al. The BRAF mutation is associated with the prognosis in colorectal cancer. J. Cancer Res. Clin. Oncol. 2014, 140:1863-1871.
3. Bokemeyer C., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 2012, 48:1466-1475.
4. Bokemeyer C., et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer 2015.
5. Bronte G., et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front. Biosci. (Elite Ed.) 2011, 3:879-887.
6. Bronte G., Rolfo C., Peeters M., Russo A. How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opin. Biol. Ther. 2014, 14:743-748.
7. Bronte G., et al. Monoclonal antibodies in gastrointestinal cancers. Expert Opin. Biol. Ther. 2013, 13:889-900.
8. Bronte G., et al. Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opin. Biol. Ther. 2015, 15:45-59.
9. Chiappa A., et al. The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit. Rev. Oncol. Hematol. 2009, 72:65-75.
10. Choti M.A., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg. 2002, 235:759-766.
11. Chua T.C., Saxena A., Chu F., Zhao J., Morris D.L. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J. Surg. Oncol. 2011, 103:796-800.
12. De Roock W., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
13. Di Nicolantonio F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:5705-5712.
14. Douillard J.Y., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369:1023-1034.
15. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 1999, 230:309-318. (discussion 318-321).
16. Francesca Bergamo M.S., Loupakis Fotios, et al. J. Clin. Oncol. 2014, 34(Suppl. 3). (abstr 476).
17. Garden O.J., et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006, 55(Suppl. 3):iii1-iii8.
18. Hecht J.R., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:672-680.
19. Heinemann V., Von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15(September (10)):1065-1075.
20. Karagkounis G., et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013, 119:4137-4144.
21. Kastrinakis W.V., Ramchurren N., Maggard M., Steele G., Summerhayes I.C. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch. Surg. 1995, 130:9-14.
22. Kemeny N.E., et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014, 120:3965-3971.
23. Kim M.J., et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012, 12:347.
24. Kopetz S., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009, 27:3677-3683.
25. Ksienski D., Woods R., Speers C., Kennecke H. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann. Surg. Oncol. 2010, 17:3085-3093.
26. Mann C.D., Metcalfe M.S., Leopardi L.N., Maddern G.J. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch. Surg. 2004, 139:1168-1172.
27. Maughan T.S., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
28. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 2010, 8:336-341.
29. Nagashima I., Takada T., Nagawa H., Muto T., Okinaga K. Proposal of a new and simple staging system of colorectal liver metastasis. World J. Gastroenterol. 2006, 12:6961-6965.
30. Nagashima I., et al. Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J. Gastroenterol. 2006, 12:6305-6309.
31. Nash G.M., et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann. Surg. Oncol. 2010, 17:572-578.
32. Nordlinger B., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996, 77:1254-1262.
33. Price T.J., et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of Capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancer. J. Clin. Oncol. 2011, 29:2675-2682.
34. Richman S.D., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 2009, 27:5931-5937.
35. Rizzo S., et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat. Rev. 2010, 36(Suppl. 3):S56-S61.
36. Rolfo C., Russo A., Santini D., Bronte G., Peeters M. Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. Expert Opin. Ther. Targets 2013, 17:869-871.
37. Rolfo C., et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev. Gastroenterol. Hepatol. 2014, 8:875-885.
38. Russo A., et al. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif. 1998, 31:139-153.
39. Russo A., et al. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2009, 77(Suppl. 1):57-68.
40. Schirripa M., et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br. J. Cancer 2015.
41. Schwartzberg L.S., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014, 32:2240-2247.
42. Sridhar S.S., Hedley D., Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 2005, 4:677-685.
43. Stremitzer S., et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br. J. Surg. 2012, 99:1575-1582.
44. Suchy B., Zietz C., Rabes H.M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int. J. Cancer 1992, 52:30-33.
45. Tanaka M., Omura K., Watanabe Y., Oda Y., Nakanishi I. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J. Surg. Oncol. 1994, 57:57-64.
46. Taylor A., Kanas G., LW, et al. Ann. Oncol. 2010, 21(Suppl. 8):632P.
47. Tejpar S., et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 2012, 30:3570-3577.
48. Teng H.W., et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J. Surg. Oncol. 2012, 106:123-129.
49. Tie J., et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin. Cancer Res. 2011, 17:1122-1130.
50. Tol J., et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur. J. Cancer 2010, 46:1997-2009.
51. Tran B., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117:4623-4632.
52. Vakiani E., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 2012, 30:2956-2962.
53. Van Cutsem E., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 2015, 33:692-700.
54. Varghese H.J., et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res. 2002, 62:887-891.
55. Vauthey J.N., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann. Surg. 2013, 258:617-626.
56. Webb C.P., Van Aelst L., Wigler M.H., Vande Woude G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:8773-8778.
57. de Jong M.C., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann. Surg. 2009, 250:440-448.